🇺🇸 FDA
Pipeline program

Stapokibart

CQMU-2025-215

Unknown mab active

Quick answer

Stapokibart for Primary Cutaneous Amyloidosis is a Unknown program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Primary Cutaneous Amyloidosis
Phase
Unknown
Modality
mab
Status
active

Clinical trials